WebMay 30, 2024 · TPS3112 Background: Bispecific antibodies to facilitate T-cell directed cytotoxicity (TDCC) is a proven therapy strategy in cancer. ERY974 is a humanized IgG4 bispecific antibody designed to simultaneously bind to cytotoxic T-cell CD3 receptors and GPC3 (a glycoprotein expressed on cell surface of several tumors) to elicit T-cell … WebPharmacokinetics of ERY974 in combination with atezolizumab and bevacizumab from initiation [Concomitant use part] [ Time Frame: From first dose until 28 days after the last dose of study treatment, assessed up to about 52 weeks. ] Uncorrected QT interval, QTcF, PR duration, QRS interval and RR interval. 12.
Recent advances and challenges of bispecific antibodies …
WebFeb 1, 2024 · Then, we will describe the identification and optimization process for ERY974, an anti-glypican-3 × anti-CD3ε T cell-redirecting bispecific antibody with a common light chain. This format includes one of Chugai's proprietary technologies, termed ART-Ig technology, which consists of a method to identify a common light chain, isoelectric point ... WebApr 1, 2024 · (A) aCD3 mAb, and OKT-3 (B) ERY974 and ERY974/aCD3 mAb, for which the X axis shows the concentration of ERY974. Fig. 4. Percentages of CD25+ or CD69+ cells in CD4+ T cells and CD8+ T cells. hotelli lentokentällä
Daniel Weiss, MD, CPI - VP & Head of Early Clinical …
WebJul 1, 2024 · ERY974 demonstrates T cell-dependent cellular cytotoxicity in vitro and transient cytokine elevations in preclinical toxicology studies (Ishiguro et al. 2024). The primary objective of this dose escalation (DE) … WebJun 28, 2024 · Clinical Trial NCT05022927; A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma October 31, 2024 updated by: ... Clinical Trials on ERY974. NCT02748837 Completed A Study of ERY974 in Patient With Advanced Solid Tumors. Solid Tumors Sponsors and Collaborators. Mayo Clinic; WebNov 17, 2024 · ERY974, which is currently in a phase I trial in patients with advanced solid tumours (ClinicalTrials.gov identifier: NCT02748837), is one of a growing list of bispecific antibodies that target ... hotelli linnanpuisto oy